At ASCO a number of studies showed the efficacy data of combining 5-FU or Xeloda with oxaliplatin in combination with radiation therapy in patients with rectal cancer. Read the rest of this entry »

Researchers tried to push the envelope in treating rectal and anal cancer by adding new or different chemotherapy to standard chemoradiotherapy.  However, two trials in rectal cancer and one in anal cancer were not able to improve complete response rates for chemoradiation.  Adding extra chemotherapy after radiation was finished didn’t improve relapse-free survival for anal cancer either. Read the rest of this entry »

The more tumors shrink during chemotherapy and radiation before rectal cancer surgery, the better the chance that patients will survive and be cancer-free five years later.

Doctors in Ireland developed a simple, three point, tumor regression grade or TRG, to measure the amount of change during chemoradiotherapy before surgery to remove rectal cancer.  After five years, all patients with the best tumor regression grade — complete or near complete response to chemoradiation — were alive and disease-free. Read the rest of this entry »

Patients whose tumors shrink in response to radiation therapy before surgery for rectal cancer have both improved overall survival and improved disease-free survival.  However, even patients who responded to presurgical radiation did not reach survival rates for stage I rectal cancer patients treated with surgery alone. Read the rest of this entry »

Focus on Clinical Trials

Can adding Avastin® (bevacizumab) to FOLFOX therapy after surgery and presurgical chemoradiotherapy reduce recurrence and improve survival for patients with rectal cancer?

A clinical trial to answer this question is underway and is looking for participants.  Led by a team of researchers from several clinical trials cooperative groups, the E5204 study randomly assigns patients who have already completed a course of chemoradiotherapy and had their rectal cancer removed surgically to either FOLFOX or FOLFOX plus Avastin. Read the rest of this entry »